Watchlist

Watchlist
Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam Pharmaceuticals, Inc. (ALNY)
2018 Brings New Challenges And Opportunities For Alnylam Pharmaceuticals
By any reasonable set of standards, 2017 was a successful year for Alnylam ( ALNY ), as this biotech reported excellent data from the pivotal study of its lead drug patisiran and advanced other compounds further into development as well. This year will bring a new set of challenges, includin…
Alnylam Pharmaceuticals (ALNY) Presents At BIO CEO & Investor Conference - Slideshow
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more …
Biotech Forum Daily Digest For February 12th
T here are some days we can claim and there are other days that claim us . Kamand Kojouri Investors got treated like 'rented mules' this week as the markets suffered their worst weekly loss in some two years. Four of the five trading sessions featured over 1,000 point sw…
Key events next week - healthcare
Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more …
Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results
Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i…
Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2017 Results - Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2017 Earnings Conference Call February 08, 2018 4:30 PM ET Executives Christine Lindenboom Vice President-Investor Relations and Corporate Communications John Maraganore Chief Executive Officer Akshay Vaishnaw Exe…
Alnylam Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more …
Alnylam Pharmaceuticals beats by $0.19, beats on revenue
Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q4 EPS of -$1.20 beats by $0.19 . Revenue of $37.9M (+117.2% Y/Y) beats by $16.1M . Press Release More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity
Reported Final Results from APOLLO Phase 3 Study and Completed Filings of New Drug Application (NDA) and Marketing Authorisation Application (MAA) for Patisiran, with an Expected Commercial Launch in U.S. and Europe in Mid- and Late 2018, Respectively Advance…
Notable earnings before Thursday's open
ABB , ALNY , ALXN , BCE , BR , BWA , CAH , CBG , CBM , COR , COTY , CVS , EPC , FAF , GLPI , GOOS , GPI , GRA , GRUB , GT , GWR , HBI , K , KKR , LCII , MANU , MAS , MD , MDSO , MLCO , MMS , MMYT , MPW , NJR , NLSN , NS , NYT , ODFL , PAG , PENN , PM…
Alnylam Pharmaceuticals, Inc. (ALNY)